Abstracts tagged "observation and rheumatoid arthritis (RA)"

Abstract Number: 536 • 2018 ACR/ARHP Annual Meeting
Prevalence and Relative Factors for Frailty in Patients with RA from a Prospective Observational Study
Masahiro Tada¹, Yutaro Yamada², Koji Mandai³ and Noriaki Hidaka⁴, ¹Orthopaedic Surgery, Osaka City General Hospital, Osaka, Japan, ²Orthopedic surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ³Orthopaedic surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ⁴Orthopaedic surgery, Osaka City General Hospital, Osaka, Japan
Prevalence and relative factors for frailty in patients with RA from a prospective observational study Background/Purpose: Frailty is defined as degradation of physical and cognition…
Abstract Number: 2537 • 2018 ACR/ARHP Annual Meeting
Benefit Study: Results of Interim Analysis of a Pan-European Observational Study to Evaluate Real-World Effectiveness of SB4 Following Transition from Originator Etanercept (ETN) in Patients with Rheumatoid Arthritis (RA) or Axial Spondyloarthritis (AxSpA)
Klaus Krüger¹, Carlo Selmi^2,3, Alain Cantagrel⁴, Miguel A. Abad⁵, Ulrich Freudensprung⁶, Mourad Farouk Rezk⁶ and Janet Addison⁷, ¹Medical Centre of Rheumatology, Munich, Germany, ²Rheumatology and Clinical Immunology Unit, Humanitas Research Hospital, Rozzano (MI), Italy, ³BIOMETRA Department, University of Milan, Milan, Italy, ⁴Center of Rheumatology of CHU, Toulouse, France, ⁵FEA Reumatología, Hospital Virgen del Puerto, Cáceres, Spain, ⁶Biogen International GmbH, Zug, Switzerland, ⁷Biogen Idec, Maidenhead, United Kingdom
Background/Purpose: SB4, a biosimilar to the reference ETN, received EU marketing authorisation in January 2016, based on the totality of evidence from pre-clinical and clinical…
Abstract Number: 1039 • 2017 ACR/ARHP Annual Meeting
Influences for Therapeutic Changes in Rheumatoid Arthritis Patients from the Veterans Affairs Rheumatology Arthritis Registry Who Have Moderate to High Disease Activity
Brian Sauer¹, Jacob R. Stever¹, Chia-Chen Teng, MS¹, Neil Accortt², David Collier² and Grant Cannon¹, ¹Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Amgen Inc., Thousand Oaks, CA
Background/Purpose: Current guidelines encourage the measurement of rheumatoid arthritis (RA) disease activity to achieve a low disease state (treat-to-target). Many RA patients with documented moderate…
Abstract Number: 1364 • 2017 ACR/ARHP Annual Meeting
Incidence of Rheumatoid Arthritis in a Cohort of First Degree Relatives from the Studies of the Etiology of Rheumatoid Arthritis
Diraj R. Karnani¹, Lindsy J. Forbess², Michael Weisman³, Kevin D. Deane⁴, V. Michael Holers⁵ and Jill M. Norris⁶, ¹Department of Rheumatology, Cedars Sinai Medical Center, Los Angeles, CA, ²Medicine, Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ³Cedars-Sinai Medical Center Division of Rheumatology, Los Angeles, CA, ⁴Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁵Rheumatology Division, University of Colorado School of Medicine, Aurora, CO, ⁶Department of Epidemiology, Colorado School of Public Health, Aurora, CO
Background/Purpose: First-degree relatives (FDRs) of patients with rheumatoid arthritis (RA) are at increased risk for developing RA compared to the general population. The purpose of…
Abstract Number: 584 • 2015 ACR/ARHP Annual Meeting
Positivity for Rheumatoid Factor Is Associated with a Better Short-Term Response and Long-Term Drug Retention of Abatacept: Results from Consecutive 508 Patients with Rheumatoid Arthritis in a Japanese Multicenter Registry
Nobunori Takahashi¹, Toshihisa Kojima¹, Koji Funahashi² and Naoki Ishiguro³, ¹Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ²Nagoya University Hospital, Nagoya, Japan, ³Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan
Background/Purpose: Abatacept (ABT) is a biologic drug and has been available for rheumatoid arthritis (RA) patients since 2010 in Japan. There have still been few…
Abstract Number: 3197 • 2015 ACR/ARHP Annual Meeting
Clinical Practice Experience in Rheumatoid Arthritis Patients Treated with Triple Therapy and Methotrexate-Tumor Necrosis Factor Inhibition Differs from That of Randomized Controlled Trials
Daniel Erhardt¹, Brian Sauer², Chia-Chen Teng³, Ted R. Mikuls⁴, Jeffrey R. Curtis⁵, Derek Tang⁶, Bradley S. Stolshek⁶ and Grant W. Cannon¹, ¹Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ³HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Amgen, Inc., Thousand Oaks, CA
Background/Purpose: Recently published randomized controlled trials (RCTs) have demonstrated similar outcomes in rheumatoid arthritis (RA) patients treated with triple therapy [methotrexate (MTX), sulfasalazine (SUL) and…
Abstract Number: 42 • 2015 ACR/ARHP Annual Meeting
Does the Risk of Mortality in Patients with RA Change over Time or Disease Duration?
Kaleb Michaud^1,2, Sofia Pedro², Bryant R. England³ and Frederick Wolfe², ¹Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²National Data Bank for Rheumatic Diseases, Wichita, KS, ³Division of Rheumatology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Observational studies have shown an increased risk of mortality in patients with RA, though none have done so with patients from all 50 US…
Abstract Number: 130 • 2015 ACR/ARHP Annual Meeting
Disease Activity Patterns in Incident Onset Rheumatoid Arthritis Patients in the First 3-Years of Follow up
Mark Tatangelo¹, George A. Tomlinson², Bindee Kuriya³ and Claire Bombardier⁴, ¹University of Toronto, Toronto, ON, Canada, ²Medicine, Mount Sinai Hospital, Toronto, ON, Canada, ³Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁴Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: Disease progression in longitudinal studies of rheumatoid arthritis (RA) is usually assessed by examining a measure of disease over time fixed time intervals. We…
Abstract Number: 2414 • 2014 ACR/ARHP Annual Meeting
Etanercept in Mono Therapy or in Combination with MTX: Results from a Sub Analysis of a German Non-Interventional Study
Karl Heinz Goettl¹, Markus Gaubitz², Andreas Krause³, Udo Lendl⁴, Ralph Lippe⁴, Thomas Meng⁴ and Peter-Andreas Loeschmann⁵, ¹Joint practice for internal medicine, Passau, Germany, ²Academy of manual diagnostic at University of Münster, Münster, Germany, ³Konigstr. 63, Immanuel Krankenhaus Berlin, Berlin, Germany, ⁴Pfizer Pharma GmbH, Berlin, Germany, ⁵Loeschmann, Berlin, Germany
Background/Purpose Although a combination with MTX is recommended for all biologics, data from different registries around the world show that in real life around 30%…
Abstract Number: 480 • 2014 ACR/ARHP Annual Meeting
Serious Infection Risk By Treatments and Types in Patients with RA
Kaleb Michaud^1,2, Sofia Pedro¹, Andre Kalil³, Ted R. Mikuls⁴ and Frederick Wolfe¹, ¹National Data Bank for Rheumatic Diseases, Wichita, KS, ²Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ³Infectious Diseases, University of Nebraska Medical Center, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Recent studies provide conflicting results on the impact of DMARDs on the risk of serious infections for patients with RA. We examined these infection…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].